Clinical trial NCT05625932: TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer
Official title: Prophylaxis of Venous Thromboembolic Disease With Low Molecular Weight (LMWH) (TINzaparin) in Patients With Metastatic Colorectal Cancer Who Start the First Line of Treatment.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Colorectal Cancer Metastatic
Thromboembolism
Keywords: LMWH
Prophylaxis
Thromboembolic event
Colorectal cancer
Lead sponsor: Galician Research Group on Digestive Tumors
Sponsor class: OTHER
Collaborators: name: LEO Pharma
First posted: 2022-11-23
Enrollment: 526
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two-arm, randomized, non-placebo controlled, open-label
Primary purpose: PREVENTION

Brief summary: Patients with metastatic colorectal cancer (mCRC) who are scheduled to receive systemic cancer therapy have an increased risk for venous thromboembolic (VTE) events compared with the general population.

PROTINCOL is a randomized, open label, non placebo-controlled, low intervention, and phase III clinical trial that will recruit patients with mCRC. The study hypothesizes that prophylaxis with Tinzaparin could prevent the appearance of symptomatic and incidental VTE.

All patients will receive the first-line anticancer treatment deemed more appropriate according to the physician criteria. Enrolled patients are randomized in a 1:1 ratio (stratifying by BRAF/RAS, resection of primary tumor, and anti-angiogenic first-line treatment) to: control arm (no interventions related to VTE risk and no placebo) or experimental arm (prophylactic Tinzaparin at a fixed dose of 4500 IU/day in patients with up to 80kg, 6000 IU/day for those between 80-100 kg, or 8000 IU/day for those \>100kg). Treatment is scheduled for a maximum period of 4 months. Treatment could be stopped earlier in case of unacceptable toxicity, patient consent withdrawal, physician criteria or end of study. Patients will undergo tumor and VTE assessments according to standard clinical practice.

The main objective of the study is to evaluate the efficacy of tinzaparin for the prevention of symptomatic or incidental VTE events. Secondary objectives include the associations between VTE events and tumor characteristics (i.e. laterality, RAS/BRAF mutations) or management (i.e. surgery or treatment with anti-angiogenic or anti-EGFR agents), cancer-specific survival outcomes, safety, the incidence of bleeding events, and patient-reported quality of life. The trial includes also a translational exploratory analysis to assess the predictive value of risk assessment models and genetic risk scores, their evolution through the study and microsatellite instability or other biomarkers.

Detailed description: This research study is a prospective, randomized, open label (PROBE), non placebo-controlled, and phase III clinical trial; Investigator Initiated Study (IIS). The study has been considered a low-interventional clinical trial.

The trial will compare the efficacy and safety of tinzaparin with a watch and wait strategy for primary prophylaxis of symptomatic or incidental VTE in adult men and women, 18 years of age and older, with metastatic colorectal cancer who are scheduled to initiate systemic cancer therapy as a component of their standard of care anticancer regimen.

The study consists of 3 periods: a 4-week screening period, a 4 months treatment period and post-treatment follow-up period until the end of treatment (EOT) visit, scheduled 2 months after the last dose of tinzaparin or 6 months from the first dose of tinzaparin (whichever occurs latest). The duration of participation in the study for each subject is approximately 6 months. Further long-term phone follow-up to monitor for progression and survival could be carried out at the end of study. Tumor follow-up assessments will adhere to the standard clinical practice within each site.

All patients will receive the first-line anticancer treatment deemed more appropriate according to the physician criteria and current guideline recommendations. Patients in both groups will receive supportive care as per local practice. No formal recommendations will be issued by the study protocol regarding cancer treatment and supportive care, but the drugs used will be recorded in the clinical report form. Constitutive use of anticoagulant drugs will be prohibited during the treatment period.

Enrolled patients are randomized in a 1:1 ratio to the control arm, or the experimental arm:

Control arm: A watch and wait strategy will be used. There is no placebo. Since no reference treatment is available for long-term VTE prophylaxis in patients with cancer, patients in the control group will not receive VTE prophylaxis outside the hospital and will receive anticancer treatment and supportive care as per local practice. No formal recommendations will be issued by the study protocol regarding cancer treatment and supportive care, but the drugs used will be recorded in the clinical report form (CRF). Patients in the control group will receive antithrombotic prophylaxis as per local practice during hospitalizations. Any use of LMWH will be recorded in the CRF.

Experimental arm: Patients will receive prophylaxis tinzaparin at a fixed dose daily for 4 months.

The primary objective is to evaluate the efficacy of 4-months prophylaxis with tinzaparin for the prevention of symptomatic or incidental VTE events. Secondary efficacy objectives include the VTE incidence in specific subpopulations (stratification according to the laterality of the primary tumor, first-line treatment with anti-EGFR or antiangiogenics, and mutational status).

Safety of tinzaparin will be evaluated by means of relevant adverse events, incidence of bleedings according to International Society of Thrombosis and Hemostasis (ISTH) criteria, and patient-reported quality of life. Bleeding events will be evaluated locally by the investigator and centrally by a blinded committee.

Eligibility criteria: Inclusion Criteria:

1. Male or female subjects with age ≥ 18 years.
2. Written informed consent.
3. Patients with a histologically confirmed diagnosis of stage IV colon or rectal adenocarcinoma (mCRC).
4. Locally assessed BRAF and RAS genomic alterations available during screening.
5. Beginning of the first line of treatment for metastatic disease with chemotherapy +/- targeted therapy (i.e. antiangiogenic, anti-EGFR, encorafenib-cetuximab doublet) or immunotherapy.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
7. Life expectancy \>6 months.

Exclusion Criteria:

1. Contraindication to tinzaparin, or other heparins:

   1. Allergy (or hypersensitivity) to heparin, tinzaparin, other LMWHs, or pork products.
   2. History or presence of heparin-induced (type II) thrombocytopenia.
   3. Have or have had an epidural catheter or a traumatic spinal puncture within the previous 7 days.
2. Prothrombin time (PT) (International normalized ratio \[INR\] \>1.5 for any reason) or aPTT \>2 times control value.
3. Active major bleeding or conditions predisposing to major bleeding. a major bleeding is defined as one that meets one of the following three criteria:

   1. occurring in a critical area or organ (for example, intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular or pericardial, intrauterine or intramuscular with compartment syndrome),
   2. causing a decrease in hemoglobin levels of 2 g/l (1.24 mmol/l) or more, or that requires a transfusion of two or more units of whole blood or packed red blood cells.
4. Lesions or conditions at increased risk of clinically significant bleeding, including:

   1. Previously diagnosed/treated VTE ≤ 28 days prior to randomization.
   2. Active ulcer disease.
   3. Diagnosed cerebral metastases.
   4. Stroke within the prior 6 months.
   5. History of central nervous system (CNS) or intraocular bleeding.
5. Requirement of other anticoagulant therapy, dual antiplatelet therapy, daily non-steroidal anti-inflammatory drugs, or other medications known to increase the risk of bleeding.

   Note: A daily dose of ≤100 mg of aspirin and single agent clopidogrel are permitted
6. Acute or chronic renal insufficiency with Creatinine clearance \< 30 ml / min.
7. Platelet count \< 80.000 /ml at the time of inclusion.
8. Severe liver insufficiency as defined by clinical manifestations of ascites, cirrhosis, encephalopathy and/or jaundice and/or biochemical abnormalities in liver function tests including:

   1. elevated levels of total bilirubin (\> 2 times the upper limit normal \[ULN\]),
   2. elevated liver transaminases (\> 2 times the ULN; \> 5 in case of hepatic metastasis).
9. Participating in another study of an investigational agent at the time of enrollment. Note: Use of an experimental regimen of an approved product is not cause for exclusion.
10. Patients who weigh \< 50 Kg.
11. Women of childbearing potential (WOCBP), must provide a negative serum or urine pregnancy test at screening. Women breastfeeding are not eligible.

    Note: A pregnancy test is performed on WOCBP as per standard of care for patients undergoing anticancer treatments.
12. Any underlying medical or psychiatric disorder, which, in the opinion of the investigator, makes the administration of tinzaparin unsafe or interferes with the informed consent process or trial procedures.

Primary outcomes:
measure: Incidence of any VTE
timeFrame: Throughout the study period, approximately 6 months per patient
Secondary outcomes:
measure: Incidence of symptomatic non-fatal PE
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of sllDVT
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of sueDVT
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of incidentally diagnosed PE or proximal DVT
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of symptomatic central venous catheter thromboembolism
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of iVVT
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of sVVT
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of VTE-related deaths
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of confirmed VTE events in BRAF/RAS mutated patients
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of confirmed VTE events in resected or not resected patients
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of confirmed VTE events in patients with antiangiogenic therapy
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of confirmed VTE events in patients with anti-EGFR therapy
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of confirmed VTE events in patients according to tumor laterality
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of confirmed VTE events in patients according to progression (PD)
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of confirmed VTE events in patients according genetic risk scores
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of confirmed VTE events in patients according to blood type
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of arterial thromboembolic events (ATE)
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Thrombosis-free survival (TFS)
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Event-free survival (EFS)
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Progression-free survival (PFS)
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Overall survival (OS)
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Mortality rate
timeFrame: Throughout the study period, approximately 2 years
measure: Incidence of relevant adverse events (AE)
timeFrame: Throughout the study period, approximately 2 years
measure: Incidence of treatment-related AEs (TRAEs)
timeFrame: Throughout the study period, approximately 2 years
measure: Incidence of major bleeding (MB) events
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of Clinically relevant non-major bleeding (CRNMB)
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Quality of life score
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of bleeding events in BRAF/RAS mutated patients
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of bleeding events according to surgery
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of bleeding events according to antiangiogenic therapy
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of bleeding events according to anti-EGFR therapy
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of bleeding events according to tumor laterality
timeFrame: Throughout the study period, approximately 6 months per patient
measure: Incidence of bleeding events according to genetic risk
timeFrame: Throughout the study period, approximately 6 months per patient
Other outcomes:
Locations:
city: Santiago De Compostela
country: Spain
facility: Hospital Clínico Universitario de Santiago CHUS
state: A Coruña
city: Alcoy
country: Spain
facility: Hospital Público Verge dels Lliris
state: Alicante
city: Palma De Mallorca
country: Spain
facility: Hospital Universitario Son Espases
state: Baleares
city: Badalona
country: Spain
facility: ICO (Institut Català d'Oncologia) de Badalona
state: Barcelona
city: L'Hospitalet De Llobregat
country: Spain
facility: Institut Català d'Oncologia L'Hospitalet
state: Barcelona
city: Sabadell
country: Spain
facility: Consorcio Corporación Sanitaria Parc Taulí
state: Barcelona
city: Santander
country: Spain
facility: Hospital Universitario Marqués de Valdecilla
state: Cantabria
city: Alcázar De San Juan
country: Spain
facility: Hospital General La Mancha Centro
state: Ciudad Real
city: Jerez De La Frontera
country: Spain
facility: Hospital Univ. de Jerez de la Frontera
state: Cádiz
city: Alcalá De Henares
country: Spain
facility: Hospital Universitario Príncipe de Asturias (HUPA) de Alcalá de Henares
state: Madrid
city: Móstoles
country: Spain
facility: Hospital Universitario De Móstoles
state: Madrid
city: Parla
country: Spain
facility: Hospital Infanta Cristina (Parla)
state: Madrid
city: Valdemoro
country: Spain
facility: Hospital Universitario Infanta Elena
state: Madrid
city: Marbella
country: Spain
facility: Hospital Costa del Sol de Marbella
state: Málaga
city: Teruel
country: Spain
facility: Hospital Obispo Polanco De Teruel
state: Terul
city: A Coruña
country: Spain
facility: Complejo Hospitalario Universitario de A Coruña (CHUAC)
city: A coruña
country: Spain
facility: Centro Oncológico de Galicia (A coruña)
city: A Coruña
country: Spain
facility: Complejo Hospitalario Universitario de Ferrol ( Arquitecto Macide)
city: Barcelona
country: Spain
facility: Hospital de la Santa Creu i Sant Pau
city: Barcelona
country: Spain
facility: Hospital Clinic Barcelona
city: Cuenca
country: Spain
facility: Hospital General Virgen de la Luz de Cuenca
city: Lleida
country: Spain
facility: Hospital Universitario Arnau de Vilanova de Lleida
city: Lugo
country: Spain
facility: Hospital Universitario Lucus Augusti
city: Madrid
country: Spain
facility: Hospital Clinico San Carlos
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre
city: Murcia
country: Spain
facility: Hospital General Universitario Morales Meseguer
city: Ourense
country: Spain
facility: Complejo Hospitalario Universitario De Ourense
city: Pontevedra
country: Spain
facility: Complejo Hospitalario Universitario de Pontevedra
city: Salamanca
country: Spain
facility: Complejo Asistencial Universitario De Salamanca
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen del Rocio
city: Toledo
country: Spain
facility: Hospital General Universitario de Toledo
city: Valencia
country: Spain
facility: Hospital General Universitario de Valencia
city: Vigo
country: Spain
facility: Hospital Ribera Povisa
city: Vigo
country: Spain
facility: Complejo Hospitalario Universitario de Vigo (Álvaro Cunqueiro)
city: Zamora
country: Spain
facility: Complejo Asistencial de Zamora
Study officials:
affiliation: Complexo Hospitalario Universitario de Ourense (Galicia)
name: Mercedes Salgado, M.D. Ph.D.
role: STUDY_CHAIR
affiliation: Hospital Universitario Gregorio Marañón (Madrid)
name: Andrés Muñoz, M.D. Ph.D.
role: STUDY_CHAIR
References: